Skip to main content
Signal8
Madigan Catherine profile photo

Catherine Madigan

CIK: 0001914577

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Hemab Therapeutics Holdings, Inc. logo
COAG

Hemab Therapeutics Holdings, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

  • Hemab Therapeutics Holdings, Inc. logo
    COAG

    Hemab Therapeutics Holdings, Inc.

    Apr 30, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    49K shares-
  • Hemab Therapeutics Holdings, Inc. logo
    COAG

    Hemab Therapeutics Holdings, Inc.

    Jan 29, 2026
    Award(A)

    Warrants (Right to Buy)

    Direct
    145.1K shares-

1-2 of 2

About Madigan Catherine

Madigan Catherine (SEC CIK 0001914577) files insider reports with the SEC as Chief Medical Officer of Hemab Therapeutics Holdings, Inc. (COAG).

Signal8 holds 1 ownership filing by Madigan Catherine, a Form 4, filed on May 4, 2026. Those filings report 2 transactions, from Jan 29, 2026 to Apr 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Madigan Catherine's filings is in CAMBRIDGE, MA.

Recent filings by Madigan Catherine

  • Apr 30, 2026: Grant or award of COAG derivative securities (Form 4, code A).
  • Jan 29, 2026: Grant or award of COAG derivative securities (Form 4, code A).

Other insiders filing for Hemab Therapeutics Holdings, Inc. (COAG)

How to read Form 4 transaction codes